Sartorius/€SRT3
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Sartorius
Sartorius AG, trading under the ticker symbol SRT3, is a global provider of laboratory and bioprocess technologies, offering products and services that cater to the needs of the biopharmaceutical and research industries. Founded in 1870 and headquartered in Göttingen, Germany, the company specializes in filtration, fermentation, fluid management, and laboratory products, supporting clients ranging from research facilities to large-scale biopharmaceutical manufacturers. Operating internationally, Sartorius is crucial in enabling the development and production of biotech medications and vaccines, solidifying its role as a crucial player in the life sciences and biotechnology sectors.
Ticker
€SRT3
Sector
Primary listing
XETRA
Employees
13,685
Headquarters
Website
Sartorius Metrics
BasicAdvanced
€12B
-
-
1.24
€0.74
0.37%
Price and volume
Market cap
€12B
Beta
1.24
52-week high
€292.00
52-week low
€166.05
Average daily volume
7.2K
Dividend rate
€0.74
Financial strength
Current ratio
1.394
Quick ratio
0.77
Long term debt to equity
107.751
Total debt to equity
122.695
Dividend payout ratio (TTM)
48.70%
Interest coverage (TTM)
2.58%
Profitability
EBITDA (TTM)
781
Gross margin (TTM)
45.76%
Net profit margin (TTM)
3.00%
Operating margin (TTM)
13.69%
Effective tax rate (TTM)
26.64%
Revenue per employee (TTM)
€250,000
Management effectiveness
Return on assets (TTM)
2.97%
Return on equity (TTM)
4.46%
Valuation
Dividend yield (TTM)
0.37%
Forward dividend yield
0.37%
Growth
Revenue change (TTM)
3.80%
3-year revenue growth (CAGR)
-3.68%
10-year revenue growth (CAGR)
13.20%
3-year dividend per share growth (CAGR)
-16.26%
10-year dividend per share growth (CAGR)
10.82%
What the Analysts think about Sartorius
Analyst ratings (Buy, Hold, Sell) for Sartorius stock.
Bulls say / Bears say
In H1 2025, the Bioprocess Solutions division achieved 8.8% constant-currency sales growth to €1.435 billion and increased its underlying EBITDA margin to 31.6%, driven by strong demand for high-margin consumables (European Financial Times)
The Group's underlying EBITDA climbed 11.9% to €527 million in H1 2025, raising the margin by 1.7 percentage points to 29.8%, demonstrating efficient operations despite ongoing market headwinds (Reuters)
Net debt to underlying EBITDA improved to 3.8x as of June 30, 2025 from 4.0x at 2024 year-end, enhancing Sartorius’s financial flexibility and supporting its investment grade standing (European Financial Times)
The Lab Products & Services segment saw a 4.8% constant-currency sales decline to €332 million in H1 2025, with underlying EBITDA margin dropping to 22.3%, indicating ongoing weakness in lab equipment demand (European Financial Times)
Analysts noted that the trailing 12-month book-to-bill ratio for the Bioprocess Solutions division fell below 1 in Q2, leading to a 4.6% share price decline as concerns over order momentum increased (Reuters)
JP Morgan’s cautious view, with Q1 2025 underlying EBITDA estimates 3% below the consensus and lower full-year sales forecasts, triggered a roughly 4% drop in the stock, highlighting the share’s sensitivity to broker downgrades (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
Sartorius Financial Performance
Revenues and expenses
Sartorius Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sartorius stock?
Sartorius (SRT3) has a market cap of €12B as of September 17, 2025.
What is the P/E ratio for Sartorius stock?
The price to earnings (P/E) ratio for Sartorius (SRT3) stock is 0 as of September 17, 2025.
Does Sartorius stock pay dividends?
Yes, the Sartorius (SRT3) stock pays dividends to shareholders. As of September 17, 2025, the dividend rate is €0.74 and the yield is 0.37%. Sartorius has a payout ratio of 48.7% on a trailing twelve-month basis.
When is the next Sartorius dividend payment date?
The next Sartorius (SRT3) dividend payment date is unconfirmed.
What is the beta indicator for Sartorius?
Sartorius (SRT3) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.